熊本大学大学院生命科学研究部 消化器内科学分野

  • ご挨拶
  • お知らせ
    お知らせ一覧
    教室行事
    臨床研究について(オプトアウト)
  • 患者様へ
    外来のご案内
    診療案内
    入院病棟について
    画像検査
    消化器の病気Q&A
    Fib-4index計算サイト
    飲酒習慣スクリーニングテスト
  • 医療従事者の方々へ
    スタッフ紹介
    研究・業績
    診療案内
    学術奨励賞
  • 学生・研修医の皆様へ
    医局見学について
    後期研修・入局のお申込み
  • 消化器内科について
    リンク
    アクセス
  • お問い合わせ

Research & achievements研究・業績aaa

Research paper

Category
  • 研究活動

  • 研究論文和文

  • 研究論文英文

  • 学会発表

  • 主催講演会

2019年度

  • 2019年度

    Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.

    J Hematol Oncol. 2019 Dec 30;12(1):144.

    Ogawa K, Lin Q, Li L, Bai X, Chen X, Chen H, Kong R, Wang Y, Zhu H, He F, Xu Q, Liu L, Li M, Zhang S, Nagaoka K, Carlson R, Safran H, Charpentier K, Sun B, Wands JR, Dong X.
    Endoscopic ultrasound findings and pathological features of pancreatic carcinoma in situ.

    Endosc Int Open. 2019 Apr;7(4): E585-E593

    Izumi Y, Hanada K, Okazaki A, Minami T, Hirano N, Ikemoto J, Kanemitsu K, Nakadoi K, Shishido T, Katamura Y, Onogawa S, Amano H, Hino F, Amano H, Yonehara S.
    Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately.

    Ann Surg Oncol. 2019 May;26(5):1385-1393.

    Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Yane K, Tsuchiya Y, Komoto I, Tanaka H, Tsuji A, Hashigo S, Mine T, Kanno A, Murohisa G, Miyabe K, Takagi T, Matayoshi N, Sakaguchi M, Ishii H, Kojima Y, Matsuo K, Yoshitomi H, Nakamori S, Yanagimoto H, Yatabe Y, Furuse J, Mizuno N.
    Post-endoscopic retrograde cholangiopancreatography pancreatitis in patients with asymptomatic common bile duct stones.

    J Gastroenterol Hepatol. 2019; 34(7): 1153-1159

    Saito H, Koga T, Sakaguchi M, Kadono Y, Kamikawa K, Urata A, Imamura H, Tada S, Kakuma T, Matsushita I.
    Anti-tumor activity of antibody drug conjugate

    Cancer Lett. 2019 May 1; 449:87-98.

    Nagaoka K, Bai X, Ogawa K, Dong X, Zhang S, Zhou Y, Carlson RI, Jiang ZG, Fuller S, Lebowitz MS, Ghanbari H, Wands JR.
    Safety and Efficacy of Endoscopic Removal of Common Bile Duct Stones in Elderly Patients ≥90 Years of Age.

    Intern Med. 2019; 58(15): 2125-2132

    Saito H, Koga T, Sakaguchi M, Kadono Y, Kamikawa K, Urata A, Imamura H, Tada S, Kakuma T, Matsushita I.
    Risk factors for the development of post-endoscopic retrograde cholangiopancreatography pancreatitis in patients with asymptomatic common bile duct stones.

    World J Gastrointest Endosc. 2019; 11(10): 515-522

    Saito H, Kakuma T, Matsushita I.
    Lysine-specific demethylase-2 is distinctively involved in brown and beige adipogenic differentiation.

    FASEB J. 2019 Apr;33(4):5300-5311.

    Takase R, Hino S, Nagaoka K, Anan K, Kohrogi K, Araki H, Hino Y, Sakamoto A, Nicholson TB, Chen T, Nakao M.
    Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treat ment: A prospective multicenter cohort study.

    Cancer Med. 2019 Mar 22. doi: 10.1002/cam4.2061.

    Nakano M, Koga H, Ide T, Kuromatsu R, Hashimoto S, Yatsuhashi H, Seike M, Higuchi N, Nakamuta M, Shakado S, Sakisaka S, Miuma S, Nakao K, Yoshimaru Y, Sasaki Y, Oeda S, Eguchi Y, Honma Y, Harada M, Nagata K, Mawatari S, Ido A, Maeshiro T, Matsumoto S, Takami Y, Sohda T, Torimura T.
    Advanced parametric imaging for evaluation of Crohn's disease using dual-energy computed tomography enterography.

    Radiol Case Rep. 2018 Apr 24;13(3):709-712.

    Taguchi N, Oda S, Kobayashi T, Naoe H, Sasaki Y, Imuta M, Nakaura T, Yamashita Y.
    Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study.

    Hepatol Int. 2019 Feb 28. doi: 10.1007/s12072-019-09939-2.

    Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, Higuchi N, Nakamuta M, Oeda S, Eguchi Y, Shakado S, Sakisaka S, Yoshimaru Y, Sasaki Y, Honma Y, Harada M, Seike M, Maeshiro T, Miuma S, Nakao K, Mawatari S, Ido A, Nagata K, Matsumoto S, Takami Y, Sohda T, Kakuma T, Torimura T.
    Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma.

    Cancer Lett. 2019 Feb 12; 449:87-98.

    Nagaoka K, Bai X, Ogawa K, Dong X, Zhang S, Zhou Y, Carlson RI, Jiang ZG, Fuller S, Lebowitz MS, Ghanbari H, Wands JR.
    Chronic ethanol-mediated hepatocyte apoptosis links to decreased TET1 and 5-hydroxymethylcytosine formation.

    FASEB J. 2019 Feb;33(2):1824-1835.

    Ji C, Nagaoka K, Zou J, Casulli S, Lu S, Cao KY, Zhang H, Iwagami Y, Carlson RI, Brooks K, Lawrence J, Mueller W, Wands JR, Huang CK.
    Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse?

    Clin J Gastroenterol 12/P.598-302/2019

    Yukawa Y, Tamori A, Iio E, Ogawa S, Yoshida K, Uchida-Kobayashi S, Enomoto M, Tanaka Y, Kawada N.
    Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis.

    "J Dermatol  46/P.e339-e341/2019"

    Miyashita A, Fukushima S, Tsukamoto H, Itai H, Miyamoto H, Nakahara S, Kubo Y, Kimura T, Kuriyama H, Ihn H
    Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease.

    PLoS One 14/P.e0224184-/2019

    Arai T, Atsukawa M, Tsubota A, Kawano T, Koeda M, Yoshida Y, Tanabe T, Okubo T, Hayama K, Iwashita A, Itokawa N, Kondo C, Kaneko K, Kawamoto C, Hatori T, Emoto N, Iio E, Tanaka Y, Iwakiri K.
    Hepatitis B virus-related hepatocellular carcinoma in young adults Efficacy of nationwide selective vaccination.

    Hepatol Res 50/P.182-189/2019

    Yotsuyanagi H, Takano T, Tanaka M, Amano K, Imamura M, Ogawa K, Yasunaka T, Yasui Y, Hayashi K, Tanaka Y, Tajiri H; for Japanese adolescent HBV-HCC study group.
    Factors associated with longitudinal changes in serum concentrations of Mac-2 binding protein: a prospective 3-year observational study

    Nutr Metab Cardiovasc Dis 29/P.1337-1344/2019

    Sugiura T, Dohi Y, Takase H, Yamashita S, Tsuzuki Y, Ogawa S, Tanaka Y, Ohte N.
    The reduction of miR146b-5p in monocytes and T cells could contribute to the immunopathogenesis of hepatitis C virus infection.

    Sci Rep 9/P.13393-/2019

    Kondo Y, Kogure T, Ninomiya M, Fukuda R, Monma N, Ikeo K, Tanaka Y.
    Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium

    Hepatol Int 13/P.587-598/2019

    Huang C-F, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu Y-C, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu C-H, Tada T, Chuang W-L, Cheung R, Hayashi J, Tseng C-H, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang J-F, Tai C-M, Lo G-H, Lee M-H, Yang H-I, Kao J-H, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu M-L, Nguyen MH, For the REAL-C Investigators
    MEG3-derived miR-493-5p overcomes the oncogenic feature of IGF2-miR-483 loss of imprinting in hepatic cancer cells

    Cell Death Dis 10/P.553-/2019

    Gailhouste L, Liew LC, Yasukawa K, Hatada I, Tanaka Y, Kato T, Nakagama H, Ochiya T
    Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan.

    J Viral Hepat 26/P.1266-1275/2019

    Ikeda H, Waanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T.
    Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia

    Exp. Ther. Med 18/P.596-604/2019

    Kawaguchi T, Komori A, Fujisaki K, Nishiguchi S,Kato M,Takagi H, Tanaka Y, Notsumata K, Mita E, Nomura H,Shibakoge M,Takaguchi K, Hattori T, Sata M, Koike K
    Bardoxolone methyl as a novel potent antiviral agent against hepatitis B and C viruses in human hepatocyte cell culture systems.

    Antiviral Res 169/P.104537-/2019

    Nio Y, Sasai M, Akahori Y, Okamura H, Hasegawa H, Oshima M, Watashi K, Wakita T, Ryo A, Tanaka Y, Hijikata M
    Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan

    Open Forum Infect Dis 6/P.ofz185-/2019

    Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, Ikegami T, Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T
    Small Interfering RNA Screening for the Small GTPase Rab Proteins Identifies Rab5B as a Major Regulator of Hepatitis B Virus Production

    J Virol 93/P.e00621-/2019

    Inoue J, Ninomiya M, Umetsu T, Nakamura T, Kogure T, Kakazu E, Iwata T, Takai S, Sano A, Fukuda M, Watashi K, Isogawa M, Tanaka Y, Shimosegawa T, McNiven MA, Masamune A
    Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis

    J Hepatol 71/P.473-485/2019

    Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu P-S, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour J-F, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH
    Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection

    Hepatol Commun 3/P.493-503/2019

    Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, Huang CF, Tai CM, Dai CY, Huang JF, Chuang WL, Yu ML, Tanaka Y, Nguyen MH
    Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization

    Proc Natl Acad Sci U S A 116/P.8487-8492/2019

    Iwamoto M, Saso W, Sugiyama R, Ishii K, Ohki M, Nagamori S, Suzuki R, Aizaki H, Ryo A, Yun JH, Park SY, Ohtani N, Muramatsu M, Iwami S, Tanaka Y, Sureau C, Wakita T, Watashi K
    Clinical evaluation of a newly developed chemiluminescent enzyme immunoassay in Japan for hepatitis C virus core antigen.

    Jpn J Infect Dis 72/P.285-291/2019

    Inoue T, Ohike T, Ohne K, Sato S, Goto T, Tanaka Y.
    The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.

    Aliment Pharmacol Ther 49/P.1230-1241/2019

    Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K.
    The antiviral effects of human microRNA miR-302c-3p against hepatitis B virus infection.

    Aliment Pharmacol Ther 49/P.1060-1070/2019

    Hamada-Tsutsumi S, Naito Y, Sato S, Takaoka A, Kawashima K, Isogawa M, Ochiya T, Tanaka Y
    CMCDG, a novel nucleoside analog with favorable safety features, exerts potent activity against wild-type and entecavir-resistant hepatitis B virus

    Antimicrob Agents Chemother 63/P.e02143-/2019

    Higashi-Kuwata N, Hayashi S, Das D, Kohgo S, Murakami S, Hattori S-I, Imoto S, Venzon DJ, Singh K, Sarafianos SG, Tanaka Y, Mitsuya H
    Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection

    Hepatol Res 49/P.512-520/2019

    Nakashima M, Toyoda H, Tada T, Mizuno K, Iio E, Tanaka Y, Sugiyama T, Yoshimura T, Kumada T
    Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma

    J Gastroenterol 54/P.427-436/2019

    Raksayot M, Chuaypen N, Khlaiphuengsin A, Pinjaroen N, Treeprasertsuk S, Poovorawan Y, Tanaka Y, Tangkijvanich P
    Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk

    Aliment Pharmacol Ther 49/P.107-115/2019

    Hsu Y-C, Nguyen MH, Mo L-R, Wu M-S, Yang T-H, Chen C-C, Tseng C-H, Tai C-M, Wu C-Y, Lin J-T, Tanaka Y, Chang C-Y
    TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy

    J Gastroenterol 54/P.339-346/2019

    Iio E, Matsuura K, Shimada N, Atsukawa M, Itokawa N, Abe H, Kato K, Takaguchi K, Senoh T, Eguchi Y, Nomura H, Yoshizawa K, Kang J-H, Matsui T, Hirashima N, Kusakabe A, Miyaki T, Fujiwara K, Matsunami K, Tsutsumi S, Iwakiri K, Tanaka Y
    Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

    Blood 133/P.137-146/2019

    Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K
    Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study

    Hepatol Res 49/P.125-135/2019

    Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Iwashita A-N, Kondo C, Mikami S, Asano T, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K
    Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial

    J Gastroenterol 54/P.87-95/2019

    Takehara T, Sakamoto N, Nishiguchi S, Ikeda F, Tatsumi T, Ueno Y, Yatsuhashi H, Takikawa Y, Kanda T, Sakamoto M, Tamori A, Mita E, Chayama K, Zhang G, De-Oertel S, Dvory-Sobol H, Matsuda T, Stamm LM, Brainard DM, Tanaka Y, Kurosaki M
    Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study

    J Gastroenterol Hepatol 34/P.364-369/2019

    Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K
    An Association Between Core Mutations in Hepatitis B Virus Genotype F1b and Hepatocellular Carcinoma in Alaskan Native People

    Hepatology 69/P.19-33/2019

    Hayashi S, Khan A, Simons BC, Homan C, Matsui T, Ogawa K, Kawashima K, Murakami S, Takahashi S, Isogawa M, Ikeo K, Mizokami M, McMahon BJ, Tanaka Y
  • Greetingご挨拶
  • OPT OUT臨床研究について(オプトアウト)
  • Newsお知らせ
  • Event教室行事
  • Linkリンク
  • Accessアクセス
ⓒ Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University